Gene fix trial offers hope for rare immune disease
NCT ID NCT03645486
First seen Apr 25, 2026 · Last updated Jun 14, 2026 · Updated 8 times
Summary
This trial tests a new gene therapy for Chronic Granulomatous Disease (CGD), a rare immune disorder that leaves patients vulnerable to severe infections. The therapy uses a modified virus to deliver a working copy of the faulty gene into the patient's own blood stem cells. The goal is to restore immune function and reduce life-threatening infections. The study enrolls 10 patients and will follow them for 15 years to check safety and effectiveness.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC GRANULOMATOUS DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shenzhen Geno-immune Medical Institute
RECRUITINGShenzhen, Guangdong, China, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.